Abstract | OBJECTIVES: METHODS: RESULTS: Treatment with tamoxifen, raloxifene, or the pure antiestrogen ICI 182,780 inhibited proliferation of 5637 cells in vitro. In the first xenograft study, raloxifene (10, 100, or 1000 microg/day) administered by oral gavage inhibited the growth of tumors compared with placebo or untreated controls (P <0.05). In a second experiment, tamoxifen (8.3, 125, or 1250 microg/day) delivered by time-release pellet inhibited tumor growth compared with placebo-treated controls (P <0.01). A comparison study in which tamoxifen (8.3 or 125 microg/day) or raloxifene (100 microg/day) was administered by slow-release pellet demonstrated that both SERMs reduced growth compared to placebo-treated controls (P <0.05), with comparable effectiveness. There was no detectable tumor in 17 of 30 treated mice. In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment. CONCLUSIONS:
|
Authors | Guru Sonpavde, Norihiko Okuno, Heidi Weiss, Jiang Yu, Steven S Shen, Mamoun Younes, Weiguo Jian, Seth P Lerner, Carolyn L Smith |
Journal | Urology
(Urology)
Vol. 69
Issue 6
Pg. 1221-6
(Jun 2007)
ISSN: 1527-9995 [Electronic] United States |
PMID | 17572228
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogen Receptor alpha
- Estrogen Receptor beta
- Selective Estrogen Receptor Modulators
- Tamoxifen
- Raloxifene Hydrochloride
|
Topics |
- Animals
- Carcinoma, Transitional Cell
(drug therapy, metabolism)
- Cell Line, Tumor
- Estrogen Receptor alpha
(drug effects)
- Estrogen Receptor beta
(drug effects)
- Female
- Humans
- Mice
- Mice, Inbred BALB C
- Raloxifene Hydrochloride
(pharmacology, therapeutic use)
- Selective Estrogen Receptor Modulators
(pharmacology, therapeutic use)
- Tamoxifen
(pharmacology, therapeutic use)
- Transplantation, Heterologous
- Treatment Outcome
- Urogenital Neoplasms
(drug therapy)
|